Press Release

For Immediate Release

For More Information:
Contact: Beth Hamilton
Director, Marketing & Industry Affairs
800-706-5575 ext. 4205

Apotex Receives Final Approval for Fosinopril Sodium Tabs

Weston, FL (May 19, 2005) — Apotex Corp. today announced that it has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Fosinopril Tablets in 10mg, 20mg and 40mg dosage strengths. Shipments of the drug are expected to commence immediately.

Apotex’ fosinopril sodium is the generic equivalent of Bristol-Myers Squibb’s Monopril®, used to treat hypertension. Annual sales for fosinopril tablets in the U.S. are approximately $135 million.

Apotex’ fosinopril is packaged in bottles of 90 tablets.

The Apotex Group manufactures high-quality generic pharmaceuticals, used by millions of patients worldwide. Its product line includes oral solids, liquids, injectables, nasal sprays, ophthalmics and inhalation solutions.

Monopril® is a registered trademark of Bristol-Myers Squibb.

About Apotex Corp.
Apotex Corp. is the U.S. subsidiary of Apotex Inc., the largest Canadian-owned manufacturer of prescription drugs. Through its sales and marketing headquarters in Weston, Florida, operations center in Indianapolis, and research facility in Lincolnshire, Illinois, Apotex Corp. is committed to providing safe and affordable generic medicines. Products manufactured and marketed by the Apotex Group are sold in 115 countries around the world. For more information visit apotexcorp.com.